Ix

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on: 
Thursday, June 23, 2022
Letter, Article 10, Life, Exercise, Intention, Voting rights in the United States, LEI, Acquisition, Article 9 of the Constitution of Singapore, Ix, Disclosure, EC, Person, Pharmaceutical industry, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points: 
  • ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

Retrieved on: 
Wednesday, June 22, 2022
Emergent BioSolutions, Biomedical Advanced Research and Development Authority, Monkeypox virus, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, United Kingdom, U.S. Securities and Exchange Commission, Documentation, CDC, Human services, GLOBE, Cowpox, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, FDA, COVID-19, Poxviridae, Government, BARDA, IV, Xi, Vaccinia, Tonix Pharmaceuticals, Risk, Vaccine, Human, Research, Smallpox vaccine, Ix, Development, EMA, Assistant, Pharmaceutical industry, EU

The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.

Key Points: 
  • The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.
  • The FDA has not approved TPOXX for monkeypox in the US.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

Tabula Rasa HealthCare Agrees to Sell its PrescribeWellness Business to Transaction Data Systems

Retrieved on: 
Tuesday, June 21, 2022
Doctor of Philosophy, Solution, 2010 RX30, Morgan, Lewis & Bockius, Industry, Security (finance), Securities Exchange Act of 1934, LLP, COVID-19, Risk, Pharmacist, Annual report, Information technology, Data, CEO, TDS, GTCR, Company, Pharmacy, U.S. Securities and Exchange Commission, Forward-looking statement, Growth, Securities Act of 1933, Failure, PMS, NASDAQ, Drug Quality and Security Act, Health, Acquisition, Sale, SEC, Ix, Science, Partnership, BlackRock, Death, Virgin Islands, Patient, Medicine, Multimedia, Xi, Dosem, 100,000, Pharmaceutical industry, Healthcare, Risk management

MOORESTOWN, N.J., June 21, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, announced today that it has entered into a definitive agreement to sell its PrescribeWellness business, a provider of best-in-class patient relationship management solutions, to Transaction Data Systems (TDS).

Key Points: 
  • MOORESTOWN, N.J., June 21, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC),a leading healthcare technology company advancing the safe use of medications, announced today that it has entered into a definitive agreement to sell its PrescribeWellness business, a provider of best-in-class patient relationship management solutions, to Transaction Data Systems (TDS).
  • PrescribeWellness presents a highly complementary patient relationship management solution with a national footprint of more than 15,000 community and chain pharmacies.
  • TDS will add PrescribeWellness, to its industry-leading portfolio of clinical applications to support enhanced collaboration among pharmacists, providers, payers, and patients.
  • Keval Health is acting as financial advisor and Simpson Thatcher & Bartlett LLP is serving as legal advisor to Transaction Data Systems.

Gorilla Investor Webcast Update

Retrieved on: 
Friday, June 17, 2022
100,000, Originality, Prospectus, Regardless, Marketing, BCA, Solution, Time, Patent, PIPE, Technology, Person, Business architecture, Private Securities Litigation Reform Act, Proxy, Bradbury, SEC, Amend, Form, Smart city, LLP, COVID-19, Government, Securities Act of 1933, Ownership, Failure, Sale, DE, Xi, Telecom, Risk, SmartMedia, Form F-4, CVR Partners, Company, Efficiency, IOT, Acquisition, Ix, CVR, Security (finance), Cryptocurrency, Financial services, Transaction, Nasdaq, Gorilla, Webcast, Global

Webcast and accompanying investor presentation: www.gorilla-technology.com/investors .

Key Points: 
  • Webcast and accompanying investor presentation: www.gorilla-technology.com/investors .
  • The Transactions value Gorilla at a pro-forma enterprise value of approximately $720 million.
  • 2nd stage is earn-out to Gorilla shareholders or Post-Merger Holders of 8.4 million Escrow Shares less any shares issued at 1st stage.
  • Global and Gorilla undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

Retrieved on: 
Friday, June 17, 2022
Webcast, Security (finance), Gastroenteritis, IBS-D, COVID-19, Prostate cancer, Annual report, Feedback, Genta (company), Company, Cholangiocarcinoma, U.S. Securities and Exchange Commission, ABC294640, Cancer, Research, Forward-looking statement, Private Securities Litigation Reform Act, Helicobacter pylori, TEL, Vii, Marketing, EDT, Opioid, Authorization, Diarrhea, Gastritis, SEC, Ix, Redhill, Nasdaq, Patient, Xi, NTM, Risk, Crohn's disease, Online gambling, Pharmaceutical industry, Naloxegol

TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
  • The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022.
  • The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events ,and will be available for replay for 30 days.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL ) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.

Enel X and Arrival Partner to Launch Bus Trials in Italy

Retrieved on: 
Friday, June 17, 2022
Solution, Industry, COVID-19, Motor vehicle, Environment, City, CEO, Microfactory, UPS, Cyprus Securities and Exchange Commission, EVS, Enel, Forward-looking statement, Private Securities Litigation Reform Act, Growth, Risk, Annual report, Enel X, Ecosystem, NASDAQ, SEC, Ix, Partnership, Atmosphere, U.S. Securities and Exchange Commission, Certification, GLOBE, Goal, Rail transport, Transport, Vallelunga, EU

The tests will be carried out by Enel X on the basis of an analysis matrix developed in-house, to look at all the main features of the Arrival Bus.

Key Points: 
  • The tests will be carried out by Enel X on the basis of an analysis matrix developed in-house, to look at all the main features of the Arrival Bus.
  • The success of these tests will be a key building block for Enel to include the Arrival Bus within its portfolio of global electrification solutions.
  • "We are very excited to partner with Enel X and Enel X Way to assist bus operators and cities around the world as they accelerate the transition to electric vehicles, bringing cleaner air to our cities," said Avinash Rugoobur, President of Arrival.
  • Enel X Global Retail is the Enel Groups global business line that offers services to accelerate innovation and drive the energy transition.

DGAP-News: SK Geo Centric to join Loop Industries & Suez in Joint Venture

Retrieved on: 
Friday, June 17, 2022
Security (finance), Water, Carbon, Infinite, Forward-looking statement, LinkedIn, Consultant, Health, Color, Caisse, Climate, Solution, LOOP, Technology, CEO, Drinking water, CNP Assurances, Private Securities Litigation Reform Act, Engineering, Textile, CO2, NASDAQ, News, SEC, Twitter, LCA, COVID-19, GIP, Recycling, Plastic, Coronavirus, U.S. Securities and Exchange Commission, Xi, SK, SK Group, PET, Growth, Ix, Partnership, KOREA, DMT, Risk, Goal, Meridiam, QC, Loop, Central Europe

SK Geo Centric to Participate as Equal Partner in Joint Venture to Build First Infinite Loop Facility in Europe, Together with Loop Industries and Suez.

Key Points: 
  • SK Geo Centric to Participate as Equal Partner in Joint Venture to Build First Infinite Loop Facility in Europe, Together with Loop Industries and Suez.
  • Na Kyung-Soo, the CEO of SK Geo Centric said "We are thrilled to participate in the Infinite Loop Europe project together with SUEZ, a leading French environmental services company and LOOP, which possesses an advanced recycling technology."
  • "Their extensive global expertise in petrochemical manufacturing will be invaluable in complementing the strengths that Loop and Suez will bring to the joint venture.
  • Follow Loop on Twitter: @loopindustries , Instagram: loopindustries , Facebook: Loop Industries and LinkedIn: Loop Industries
    This news release contains "forward-looking statements" as defined in the U.S.

Entegris, Inc. Announces Pricing of Private Offering of Senior Unsecured Notes

Retrieved on: 
Friday, June 17, 2022
Semiconductor, Hardware, Manufacturing, Other Manufacturing, Technology, Security (finance), Prospectus, Leadership, Vii, Regulation, Securities Act of 1933, Borrowing base, Health, CMC, Solution, AND, Annual report, Person, Compliance, Engineering, SEC, ANY, Nasdaq, Pandemic, Form, Registration statement, Intellectual property, COVID-19, Epidemic, Government, Form 10-K, Coronavirus, U.S. Securities and Exchange Commission, Xi, Risk, AS, Safety, Research, Register, SEC Rule 144A, THE, Ix, Sale, Entegris, Mergers and acquisitions

The gross proceeds of the notes, together with certain additional amounts, will be deposited into a separate escrow account for the notes until the consummation of the Merger.

Key Points: 
  • The gross proceeds of the notes, together with certain additional amounts, will be deposited into a separate escrow account for the notes until the consummation of the Merger.
  • The notes will initially be secured by the amounts deposited in the applicable escrow account.
  • Following such merger and assumption, the notes will be senior unsecured obligations of Entegris and guaranteed by each of Entegris and CMCs existing and future domestic subsidiaries, other than certain excluded subsidiaries, to the extent that such entities guarantee the term loan facility or Entegris outstanding senior unsecured notes or certain other indebtedness.
  • The offering is not being made to any person in any jurisdiction in which the offer, solicitation or sale is unlawful.

PROG Holdings Provides Second Quarter Update and Revised Full Year Outlook

Retrieved on: 
Thursday, June 16, 2022
Software, Personal Finance, Finance, Banking, Professional Services, Technology, Apps, Applications, Fintech, GMV, Industry, FTC, XV, COVID-19, EPS, Infection, Method, Progressive, Forecasting, Housing, Company, Adoption, Pressure, POS, EBITDA, Depreciation, Strategic planning, Vii, Pain, Share repurchase, Acquisition, News, Sale, SEC, Ix, Food, Software, GAAP, Xi, NYSE, Risk, Renewable energy, Insurance, Bank

PROG Holdings, Inc. (NYSE:PRG), the fintech holding company for Progressive Leasing, Vive Financial, and Four Technologies, today provided an estimate of several second quarter performance metrics as well as an update to its 2022 full year outlook.

Key Points: 
  • PROG Holdings, Inc. (NYSE:PRG), the fintech holding company for Progressive Leasing, Vive Financial, and Four Technologies, today provided an estimate of several second quarter performance metrics as well as an update to its 2022 full year outlook.
  • As a result, key national and regional point-of-sale partners are seeing a decrease in demand from our customer base, said PROG Holdings President and CEO Steve Michaels.
  • While much remains uncertain about the near term, we intend to aggressively manage our lease portfolio performance within historical targeted annual ranges.
  • PROG Holdings expects its quarterly and full-year financial results to reflect the recent deterioration across the retail and consumer environment and is providing an update on second quarter performance along with revising its full-year 2022 consolidated outlook.

Digital Health to Acquire VSee Labs and iDoc Telehealth Solutions with New Entity Valued at Approximately $110 Million

Retrieved on: 
Thursday, June 16, 2022
Digital, Security (finance), Prospectus, Forward-looking statement, Vii, Form S-1, Electronic trial master file, Communication, Delaware General Corporation Law, GLOBE, Solution, Software as a service, Annual report, CEO, Business architecture, Neurology, Hart–Scott–Rodino Antitrust Improvements Act, Tripura Merger Agreement, NASDAQ, SEC, Nasdaq, NASA, Form, ICU, Name, Industry, SPAC, Nursing, Neuro, Adoption, IDoc, Failure, Digital health, Patient, U.S. Securities and Exchange Commission, Mergers and acquisitions, Organization, Risk, Stroke, NICU, Acquisition, Ix, HIPPA, Medicine, Sale, Risk management, Online shopping, VSee

Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Digital Health Acquisition Corporation (“Digital Health”) (NASDAQ: DHAC), today announced that it has signed a definitive agreement to acquire VSee Lab, Inc. (VSee), a leading telehealth software company and iDoc Telehealth Solutions, Inc. (“iDoc”), a leading neurocritical care and intensive care telehealth provider.    The newly merged company will bring together the organizations and leadership teams of San Jose, California-based VSee, and Houston, Texas-based iDoc with the Nasdaq-listed Digital Health public company.  Upon closing of the transaction, which is expected to occur in the third quarter of 2022, it is anticipated that the combined company will adopt the corporate name VSee Health, Inc., and will be listed on the Nasdaq Capital Market under the proposed new ticker symbol “VSEE.”  The transaction is expected to result in a valuation of approximately $110 million for the combined entity.

Key Points: 
  • Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Digital Health Acquisition Corporation (Digital Health) (NASDAQ: DHAC), today announced that it has signed a definitive agreement to acquire VSee Lab, Inc. (VSee), a leading telehealth software company and iDoc Telehealth Solutions, Inc. (iDoc), a leading neurocritical care and intensive care telehealth provider.
  • The transaction is expected to result in a valuation of approximately $110 million for the combined entity.
  • The boards of directors of VSee, iDoc, and Digital Health have unanimously approved the proposed transaction.
  • Neither VSee, iDoc nor Digital Health gives any assurance that either VSee, iDoc or Digital Health or the combined company will achieve its expectations.